Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Clemens, Sue Ann Costa et al. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults. Human Vaccines and Immunotherapeutics, v. 19, n. 2, 2023. DOI: https://doi.org/10.1080/21645515.2023.2233400. Disponível em: https://www.tandfonline.com/doi/epdf/10.1080/21645515.2023.2233400?needAccess=true&role=button.
Artículo en Inglés | IED | ID: ied-6852

Documentos relacionados

  1. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
  2. SARS-CoV-2 infection and persistence in the human body and brain at autopsy.
  3. Longitudinal study comparing IgG antibodies induced by heterologous prime-boost COVID-19 vaccine.
  4. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
  5. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
  6. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
  7. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
  8. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  9. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
  10. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.